Colon Cancer Treatment - FDA Accepts ERBITUX(R) (Cetuximab) sBLA Submission for the Treatment of Squamous Cell Carcinoma of the Head and Neck
FDA Accepts ERBITUX(R) (Cetuximab) sBLA Submission for the Treatment of Squamous Cell Carcinoma of the Head and Neck
[Press Release] Business Wire via Yahoo! Finance - 1 hour, 21 minutes ago
ImClone Systems Incorporated and Bristol-Myers Squibb Company announced today that the U.S. FSave to My Web
Studies Examine the Evidence on and Outcomes of Probiotics in IBS
Newswise - Oct 30 9:14 PM
A new study of the probiotic strain B. infantis 35624 shows promising results in normalizing frequency of bowel movements in patients suffering from constipation or diarrhea - the two ends of the spectrum in Irritable Bowel Syndrome (IBS).Save to My Web
Bristol-Myers’ 3rd-Quarter Net Rises on Sale of Unit (Update5)
Bloomberg.com - Oct 28 9:21 AM
Oct. 28 (Bloomberg) — Bristol-Myers Squibb Co. said third- quarter earnings rose 27 percent on gains from the sale of its over-the-counter business. The shares dropped after the company said it may end development of a diabetes drug.Save to My Web
Study shows fused genes trigger development of prostate cancer
AngolaPress - Oct 28 5:17 AM
LOS ANGELES, 10/28 - Scrambled chromosomes and abnormal genes may cause prostate cancer, scientists reported on Thursday.Save to My Web